Antigen News and Research

RSS

TSRI scientists discover new HIV target

A team led by scientists at The Scripps Research Institute (TSRI) working with the International AIDS Vaccine Initiative (IAVI) has discovered a new vulnerable site on the HIV virus. The newly identified site can be attacked by human antibodies in a way that neutralizes the infectivity of a wide variety of HIV strains.

25 Apr 2014

Researchers develop first size-based form of chromatography using nanodot technology

Using nanodot technology, Berkeley Lab researchers have demonstrated the first size-based form of chromatography that can be used to study the membranes of living cells.

23 Apr 2014

New hypothesis about emergence of Parkinson's disease

The cause of neuronal death in Parkinson's disease is still unknown, but a new study proposes that neurons may be mistaken for foreign invaders and killed by the person's own immune system, similar to the way autoimmune diseases like type I diabetes, celiac disease, and multiple sclerosis attack the body's cells.

21 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center.

18 Apr 2014

Study: Chronic inflammation associated with aggressive prostate cancer

The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer, and this association was found even in those with low prostate-specific antigen (PSA) levels, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

18 Apr 2014

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

Neuroblastoma is one of the deadliest childhood cancers, accounting for 15 percent of pediatric cancer deaths. For patients with high-risk neuroblastomas, the five-year survival rate is 40 to 50 percent even with the most rigorous treatments available today.

17 Apr 2014

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression.

16 Apr 2014

Study: Bacterium that causes whooping cough changes in Australia

The bacterium that causes whooping cough, Bordetella pertussis, has changed in Australia - most likely in response to the vaccine used to prevent the disease - with a possible reduced effectiveness of the vaccine as a result, a new study shows.

16 Apr 2014

EventusDx completes $2.72M financing to support development, commercialization of Octava breast cancer tests

Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.

15 Apr 2014

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

A phase III clinical trial conducted at the Meir Medical Center in Kfar-Saba, Israel is now recruiting participants to study the effects of dietary supplement PectaSol-C modified citrus pectin (MCP) in controlling prostate specific antigen (PSA) levels in prostate cancer patients.

15 Apr 2014

Urologists offer new tool for visualizing, monitoring prostate in men with greater accuracy

Urologists at Rush University Medical Center are the first in Chicago to offer a powerful new tool for visualizing and monitoring the prostate in men who have high prostate-specific antigen (PSA) levels and in detecting prostate cancer more accurately.

15 Apr 2014

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

PolyTherics Limited, a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge antibody drug conjugate ("ADC") collaboration with MacroGenics Inc, a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies.

11 Apr 2014

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.

11 Apr 2014

Scientists design new system for molecular blood group typing

Scientists in France have designed a new system for molecular blood group typing that offers blood banks the possibility of extensive screening of blood donors at a relatively low cost. Their approach is described in the current issue of The Journal of Molecular Diagnostics.

10 Apr 2014

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD).

10 Apr 2014

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have started production of Immutep’s ImmuFact IMP321 (a LAG-3Ig fusion protein) at WuXi AppTec facilities in China. The product is being produced to European, U.S. and Chinese GMP standards.

8 Apr 2014

Patient-friendly examination method reduces need for prostate cancer biopsies

Each year prostate tissue samples are taken from over a million men around the world - in most cases using 12 large biopsy needles - to check whether they have prostate cancer.

8 Apr 2014

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.

7 Apr 2014

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).

7 Apr 2014

Antigen News and Research

TSRI scientists discover new HIV target

Researchers develop first size-based form of chromatography using nanodot technology

New hypothesis about emergence of Parkinson's disease

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Study: Chronic inflammation associated with aggressive prostate cancer

Study shows R9-caPep compound blocks PCNA actions in neuroblastoma cells

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

Study: Bacterium that causes whooping cough changes in Australia

EventusDx completes $2.72M financing to support development, commercialization of Octava breast cancer tests

Effects of PectaSol-C modified citrus pectin in prostate cancer patients to be studied in phase III trial

Urologists offer new tool for visualizing, monitoring prostate in men with greater accuracy

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

Adoptive T-cell therapy may help in treating liver cancer, says study

Scientists design new system for molecular blood group typing

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Patient-friendly examination method reduces need for prostate cancer biopsies

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics